AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca has released positive Phase 3 data for its experimental biologic tozorakimab, which reduced moderate and severe COPD flare-ups by approximately 30% overall and up to 34% in former smokers. The drug targets the IL-33 protein to treat a broad patient population, including those with low eosinophil counts who currently lack biologic options. Under FDA priority review with a Q1 2027 target, AstraZeneca projects peak annual sales exceeding $5 billion, positioning it to compete against established biologics like Dupixent.

Tozorakimab late-stage trial results

• ▪The Phase 3 trial data for AstraZeneca's tozorakimab was presented at the European Respiratory Society's annual conference in Barcelona and published in the New England Journal of Medicine on September 8, 2026
• ▪AstraZeneca released full results from two Phase 3 trials, named Titania and Oberon, showing that its experimental biologic drug tozorakimab significantly reduced moderate and severe chronic obstructive pulmonary disease (COPD) flare-ups
• ▪AstraZeneca's tozorakimab is currently under priority review by the U.S. Food and Drug Administration, with regulatory approval expected in the first quarter of 2027

COPD flare-up reduction rates

• ▪AstraZeneca's tozorakimab reduced moderate and severe COPD flare-ups by 23% in patients with blood eosinophil counts below 150, a group that currently has no available biologic treatment
• ▪In the primary population of former smokers, AstraZeneca's tozorakimab reduced moderate and severe COPD flare-ups by 29% and 34%, respectively, compared to a placebo
• ▪AstraZeneca's tozorakimab reduced moderate and severe COPD flare-ups by approximately 30% across the overall trial population of current and former smokers over one year

Broad patient population eligibility

• ▪Dr. Meilan Han stated that while she will likely start patients with low eosinophil levels on tozorakimab, questions remain regarding how to position the drug relative to existing biologics for patients with high eosinophil levels
• ▪AstraZeneca's tozorakimab trials included a broad patient population of both former and current smokers, spanning all blood eosinophil counts and all stages of lung function severity

IL-33 blocking mechanism

• ▪AstraZeneca CEO Pascal Soriot noted that previous industry attempts to target the IL-33 protein had limited success, leading to low initial investor expectations for tozorakimab
• ▪AstraZeneca's tozorakimab is an antibody designed to block the IL-33 protein, inhibiting two distinct inflammatory pathways to potentially address lung inflammation, mucus production, and airway damage

Five billion peak sales forecast

• ▪AstraZeneca raised its peak annual sales forecast for tozorakimab to more than $5 billion, which would support the company's overall $80 billion revenue target by 2030
• ▪AstraZeneca CEO Pascal Soriot stated that the growth potential for tozorakimab is large because only about 10% of COPD patients currently receive a biologic treatment

Competitive advantage over Dupixent

• ▪AstraZeneca's tozorakimab could reach a wider patient population than existing COPD biologics Dupixent and Nucala, which are restricted to patients with high levels of eosinophil white blood cells
• ▪No head-to-head clinical studies have been conducted to compare the efficacy of AstraZeneca's tozorakimab directly against other approved COPD biologics like Dupixent or Nucala

3 sources